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Objectives: The objective of this study was the evaluation of the performance of two commercially available
biochemical tests for the rapid detection of carbapenemase-producing Enterobacteriaceae compared with a
home-made technique.
Methods: A collection of 150 enterobacterial isolates, including 132 isolates with decreased susceptibility to at
least one carbapenem molecule, were tested for carbapenemase activity using the RAPIDECw CARBA NP
(bioMe´rieux), the Rapid CARB Screenw (Rosco Diagnostica) and the home-made Carba NP test. This strain collec-
tion included 55 non-carbapenemase producers, 21 KPC producers, 21 NDM producers, 17 VIM producers, 11 IMP
producers, 16 OXA-48 producers and 9 OXA-48-like producers (OXA-162, OXA-181, OXA-204, OXA-232 and
OXA-244).
Results: The RAPIDECw CARBA NP detected all carbapenemase producers except a single OXA-244 producer.
Using the Rapid CARB Screenw, one KPC-2, two NDM-1, one OXA-48 and five OXA-48 variant producers gave
equivocal results and one OXA-244 producer was not detected. Using the Carba NP test, the same OXA-244 pro-
ducer was not detected and one OXA-181 producer and one OXA-244 producer gave equivocal results. Sensitivity
and specificity were 99% (95% CI 94.3%–99.8%) and 100% (95% CI 93.5%–100%), respectively, for the
RAPIDECw CARBA NP test, 89.5% (95% CI 81.7%–94.2%) and 70.9% (95% CI 57.9%–81.2%) for the Rapid
CARB Screenw and 96.8% (95% CI 91.1%–98.9%) and 100% (95% CI 93.5%–100%) for the Carba NP test.
The impact of the use of an adequate bacterial inoculum for obtaining the optimal performance with the
RAPIDECw CARBA NP was noted.
Conclusions: The RAPIDECw CARBA NP possesses the best performance for rapid and efficient detection of
carbapenemase-producing Enterobacteriaceae.
Introduction
During the last decade, decreased susceptibility to carbapenems
has been increasingly reported worldwide in Gram-negative
organisms, including Enterobacteriaceae, Pseudomonas spp. and
Acinetobacter spp.1 Carbapenem resistance may result either
from the association of a decrease in outer membrane permeability
with overexpression of b-lactamases possessing very weak carba-
penemase activity, or from b-lactamases with strong hydrolytic
activity towards carbapenems, i.e. carbapenemases.2 A variety
of carbapenemases have been reported in Enterobacteriaceae,
such as KPC (Ambler class A), metallo-b-lactamases (MBLs) of
the VIM, IMP and NDM types (Ambler class B) and OXA-48-type
enzymes (Ambler class D).3 Usually carbapenemase-producing
Enterobacteriaceae (CPE) are resistant to most b-lactams and
non-b-lactam antibiotics, resulting in MDR and even pandrug-
resistant isolates.4 As a consequence, the spread of these carbape-
nemase producers represents a serious threat to public health,
especially since only a few novel antibiotics are expected in the
near future.5 Rapid and efficient detection of CPE is becoming a
major issue in limiting the spread of these highly resistant bacteria.
Recently, several methods have been developed to detect CPE.
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These methods are based on: (i) the detection of carbapenem-
hydrolysing activity by monitoring the colour change of a pH
indicator (the Carba NP test6 and its derivatives7,8) or by following
enzymatic degradation products by MALDI-TOF protocols;9 or (ii)
molecular techniques to detect the main known carbapenemase
genes.10
Considering the importance of accurately detecting CPE, our
aim was to evaluate the performance of two biochemical rapid
tests recently commercialized, the RAPIDECw CARBA NP and the
Rapid CARB Screenw, for detection of CPE, compared with the




A total of 150 strains of enterobacteria were used to evaluate the perform-
ance of the RAPIDECw CARBA NP (bioMe´rieux, La Balme-les-Grottes,
France) and the Rapid CARB Screenw (Rosco Diagnostica, Taastrup,
Denmark) in comparison with the Carba NP test.6,11 All strains had previ-
ously been characterized for their b-lactamase content at the molecular
level.6 This collection included 55 non-carbapenemase producers
(Table 1), among which 37 have decreased susceptibility to at least one
carbapenem molecule (imipenem, meropenem, ertapenem) and 95 CPE.
These CPE were of various enterobacterial species, isolated from various
clinical samples (blood cultures, urine, sputum etc.) from our own strain
collection of global origin, and included 21 KPC producers, 21 NDM produ-
cers, 17 VIM producers, 11 IMP producers, 16 OXA-48 producers and 9
OXA-48-like producers (Table 1).
Antibiotic susceptibility testing
MICs of carbapenems were determined using the Etestw (bioMe´rieux) and
results were recorded according to EUCAST guidelines, as updated in 2015
(http://www.eucast.org). Clinical carbapenem breakpoints for susceptibil-
ity/resistance were ≤2/.8 mg/L for imipenem and meropenem and
≤0.5/.1 mg/L for ertapenem.
RAPIDECw CARBA NP
The RAPIDECw CARBA NP was performed using a standardized inoculum (a
full 10 mL loop of bacterial colonies), which is critical for test reliability. The
test was performed on bacterial colonies recovered from Trypticase soy agar
(Oxoid, Dardilly, France). The bacterial inoculum was transferred from the
loop into the RAPIDECw CARBA NP using the plastic stick provided in the
kit. The RAPIDECw CARBA NP results were interpreted using the manufac-
turer’s interpretation guidelines (Figure S1A, available as Supplementary
data at JAC Online).
Rapid CARB Screenw
The Rapid CARB Screenw test was performed on bacterial colonies recov-
ered from Trypticase soy agar (Oxoid) and interpreted (Figure S1B) accord-
ing to the manufacturer’s instructions. As recommended, if an orange or
light yellow colour appeared in the tube containing the imipenem tab, the
test was repeated using a higher inoculum.
Carba NP test
The updated version of the Carba NP test was used and interpreted
(Figure S1C) as previously described.11 The test was performed on bacterial
colonies recovered from Trypticase soy agar (Oxoid).11 Reading was per-
formed within 2 h.
Results and discussion
Performance of the RAPIDECw CARBA NP, the Rapid CARB
Screenw and the Carba NP test
Preliminary experiments done with the RAPIDECw CARBA NP iden-
tified a critical impact of the bacterial inoculum on the perform-
ance of the test. Indeed, an insufficient bacterial inoculum may
yield false positive results (data not shown). Respecting the tur-
bidity positive control for the bacterial inoculum is therefore
critical. Accordingly, the bacterial inoculum has been standar-
dized as a full 10 mL loop of bacterial colonies recovered from
the Trypticase soy agar.
The RAPIDECw CARBA NP, the Rapid CARB Screenw and the Carba
NP test results for the detection of CPE and non-carbapenemase
producers are detailed in Table 2. Considering equivocal results as
invalid (false positive or false negative), sensitivity and specificity
were 99% (95% CI 94.3%–99.8%) and 100% (95% CI 93.5%–
100%), respectively, for the RAPIDECw CARBA NP, 89.5% (95% CI
81.7%–94.2%) and 70.9% (95% CI 57.9%–81.2%) for the Rapid
CARB Screenw and 96.8% (95% CI 91.1%–98.9%) and 100%
(95% CI 93.5%–100%) for the Carba NP test.
Most of the CPE isolates yielded positive results (after 2 h of incu-
bation) with the three tests (Table 1). However, using the Rapid
CARB Screenw, a single KPC-2, two NDM-1, a single OXA-48, two
OXA-181, two OXA-232 producers and a single OXA-244 producer
gave equivocal results (weakly orange) and a single OXA-244 pro-
ducer gave a negative result (Table 1). As recommended by the
manufacturer, the isolates giving equivocal results were retested
using a higher inoculum of bacteria (data not shown), leading to
positive results for the KPC-2 producer and for a single NDM-1 pro-
ducer. Despite this increased inoculum, one NDM-1 producer, one
OXA-48 producer and the five OXA-48-like producers remained
equivocal with the Rapid CARB Screenw. In addition, this test yielded
equivocal results for 29.1% (16/55) of the non-carbapenemase
producers (Table 1), which could not be resolved using a higher
inoculum (the results for the 16 non-carbapenemase-producing
isolates remained equivocal).
The Carba NP test yielded equivocal results for a single
OXA-181-producing isolate and a single OXA-244 producer
(Table 1) and was unable to detect a single OXA-244 producer
(Table 1). On the other hand, the RAPIDECw CARBA NP was able
to detect all CPE except a single OXA-244 producer. Strikingly, the
same OXA-244-producing Escherichia coli isolate gave negative/
equivocal results with all three assays. The lack of detection of car-
bapenemase activity might be explained by: (i) the lower hydrolytic
activity of OXA-244 compared with OXA-48; and/or (ii) the lower
level of expression of the enzyme, since the blaOXA-244 gene was
chromosomally located as a single copy in that strain (L. Dortet,
unpublished data). In contrast, for the OXA-244-producing E. coli
isolate that gave positive results with the RAPIDECw CARBA NP,
the blaOXA-244 gene was carried by a plasmid.
Overall, the RAPIDECw CARBA NP possessed the best per-
formance, with 99% (95% CI 94.3% – 99.8%) sensitivity and
100% (95% CI 93.5% – 100%) specificity. This performance is
in accordance with the manufacturer’s specifications [sensi-
tivity 97.8% (95% CI 93.7% – 99.2%) and specificity 97.8%
Biochemical methods for carbapenemase detection
3015
JAC
Table 1. Results of the RAPIDECw CARBA NP, the Rapid CARB Screen and the Carba NP test with carbapenemase- and non-carbapenemase-producing Enterobacteriaceae by using a
collection of carbapenemase and non-carbapenemase producers











Ambler class A carbapenemases
KPC type 1 E. coli KPC-2 ++ + ++ 1 .32 3
2 E. coli KPC-2 ++ + ++ 0.5 0.5 0.5
3 E. coli KPC-2+TEM-1+OXA-9 ++ + ++ 2 1.5 1
4 E. coli KPC-2+CTX-M-9+TEM-1 ++ + ++ 4 4 2
1 Klebsiella
pneumoniae
KPC-2+SHV-11+TEM-1+CTX-M-2 ++ + ++ 16 24 32
2 K. pneumoniae KPC-2+SHV-11+TEM-1+CTX-M-2+OXA-9 ++ + ++ .32 .32 .32
3 K. pneumoniae KPC-2+SHV-11+CTX-M-15 ++ + ++ 16 .32 .32
4 K. pneumoniae KPC-2+TEM-1+SHV-1+CTXM-15 ++ + ++ 4 4 32
5 K. pneumoniae KPC-2+SHV-11+TEM-1+SHV-12+OXA-9 ++ + ++ 4 24 2
6 K. pneumoniae KPC-2+SHV-11 ++ + ++ .32 .32 .32
7 K. pneumoniae KPC-2+SHV-11+TEM-1 ++ + ++ 4 6 8
8 K. pneumoniae KPC-3 + + ++ 8 12 2
9 K. pneumoniae KPC-3+SHV-11+OXA-9+TEM-1 ++ + ++ 8 .32 8
1 Enterobacter
cloacae
KPC-2 ++ + ++ 1 1.5 0.75
2 E. cloacae KPC-2+TEM-1 ++ + ++ 24 .32 16
3 E. cloacae KPC-2+TEM-1+OXA-1 ++ + ++ 4 6 2
4 E. cloacae KPC-2+TEM-1+SHV-11 ++ + ++ 2 4 1.5
5 E. cloacae KPC-2+TEM-3 ++ + ++ 2 2 1
1 Citrobacter
freundii
KPC-2+TEM-1 ++ + ++ 8 1.5 3
1 Serratia
marcescens
KPC-2+TEM-1+SHV-12 ++ + ++ .32 .32 .32
2 S. marcescens KPC-2+TEM-1 ++ +/2 ++ .32 .32 .32
Ambler class B carbapenemases
NDM type 1 E. coli NDM-1+OXA-1+OXA-10+CMY-16+TEM-1 ++ + ++ 1 3 1
2 E. coli NDM-1+OXA-1+TEM-1 ++ + ++ 3 3 2
3 E. coli NDM-1+CTX-M-15+TEM-1 ++ + ++ 6 32 16
4 E. coli NDM-1+OXA-1+OXA-2+CTX-M-15+TEM-1 ++ + ++ 4 .32 8
5 E. coli NDM-1+CTX-M-15+TEM-1 ++ + ++ 16 .32 16
6 E. coli NDM-4+CTX-M-15+OXA-1 ++ + ++ .32 .32 .32
7 E. coli NDM-4+CTX-M-15+CMY-6 ++ + ++ .32 .32 .32
8 E. coli NDM-5+TEM-1+CTX-M-15 ++ + ++ .32 .32 .32
9 E. coli NDM-6+CTX-M-15+OXA-1 ++ + ++ 6 32 8
10 E. coli NDM-7 ++ + ++ 4 16 3
1 K. pneumoniae NDM-1+CTX-M-15+SHV-11+OXA-1 ++ + ++ 2 8 3
2 K. pneumoniae NDM-1+CTX-M-15+CMY-4+OXA-1 ++ + ++ .32 .32 .32
3 K. pneumoniae NDM-1+CTX-M-15+OXA-1+OXA-9+TEM-1+
SHV-28+SHV-11









4 K. pneumoniae NDM-1+OXA-1+SHV-11 ++ + ++ 1.5 6 2
5 K. pneumoniae NDM-1+OXA-1+CTX-M-15+TEM-1+SHV-28+
OXA-9+CMY-6
++ + ++ 1 8 4
6 K. pneumoniae NDM-1+TEM-1+CTX-M-15+SHV-12+OXA-9 ++ + ++ 1.5 8 1.5
7 K. pneumoniae NDM-1+TEM-1+CTX-M-15+SHV-12+OXA-9 ++ + ++ 4 8 16
8 K. pneumoniae NDM-1+TEM-1+CTX-M-15+SHV-11+OXA-1 ++ + ++ 2 .32 4
1 Providencia
stuartii
NDM-1+OXA-1+CMY-6+TEM-1 ++ +/2 + 12 0.38 1.5
1 Providencia
rettgeri





++ + ++ 4 6 3
VIM type 1 E. coli VIM-1+CTX-M-3 ++ + ++ 1.5 0.38 0.5
2 E. coli VIM-1+CMY-13 ++ + ++ 3 1.5 1
3 E. coli VIM-4 ++ + ++ 8 4 3
1 K. pneumoniae VIM-1+SHV-5 ++ + ++ .32 .32 .32
2 K. pneumoniae VIM-1 ++ + ++ .32 .32 .32
3 K. pneumoniae VIM-1+SHV-12 ++ + ++ .32 .32 .32
4 K. pneumoniae VIM-1 ++ + ++ .32 .32 .32
5 K. pneumoniae VIM-1+SHV-5 ++ + ++ 4 2 2
6 K. pneumoniae VIM-1+TEM-1+SHV-5 ++ + ++ .32 .32 .32
7 K. pneumoniae VIM-1+SHV-5 ++ + ++ .32 .32 .32
8 K. pneumoniae VIM-1+CTX-M-3 ++ + ++ 1 0.5 1
9 K. pneumoniae VIM-1+SHV-5 ++ + ++ 0.5 4 0.38
10 K. pneumoniae VIM-19+CTX-M-3+TEM-1+SHV-1 ++ + ++ 8 16 4
1 E. cloacae VIM-1+SHV-70 ++ + ++ 1 0.38 0.5
2 E. cloacae VIM-4+CTX-M-15+TEM-1+SHV-31 ++ + ++ 3 2 1
1 C. freundii VIM-2+TEM-1 + ++ + ++ 2 2 0.75
2 C. freundii VIM-2+TEM-1+OXA-9+OXA-10 ++ + ++ 1.5 4 0.5
IMP type 1 E. coli IMP-1 ++ + ++ 0.5 3 0.5
2 E. coli IMP-8+SHV -12 ++ + ++ 6 8 3
1 K. pneumoniae IMP-1 ++ + ++ 1.5 3 1
2 K. pneumoniae IMP-1+TEM-15 ++ + ++ 8 3 2
3 K. pneumoniae IMP-1+TEM-1+CTX-M-15 ++ + ++ 1.5 4 2
4 K. pneumoniae IMP-1+SHV-5 ++ + ++ 1 2 8
5 K. pneumoniae IMP-8 ++ + ++ 1 1 0.5
6 K. pneumoniae IMP-8+SHV -12 ++ + ++ 0.5 0.5 0.5
1 E. cloacae IMP-8 ++ + ++ 1.5 1 1
2 E. cloacae IMP-8+SHV-12 ++ + ++ 0.75 0.5 0.5
1 S. marcescens IMP-11 ++ + ++ 8 .32 2
Ambler class D carbapenemases
OXA-48 1 E. coli OXA-48+CTX-M-15 + + ++ 3 16 1
2 E. coli OXA-48+CTX-M-15 ++ + ++ 0.5 0.75 0.12
3 E. coli OXA-48+CTX-M-15 + + + 0.38 1.5 0.19
4 E. coli OXA-48+CTX-M-24+TEM-1 + + + 0.25 0.5 0.19































2 K. pneumoniae OXA-48+TEM-1 ++ + + 0.38 1 0.5
3 K. pneumoniae OXA-48+CTX-M-15 ++ + ++ 2 3 2
4 K. pneumoniae OXA-48 ++ +/2 ++ 1 4 1
5 K. pneumoniae OXA-48 ++ + ++ 1 4 1
6 K. pneumoniae OXA-48 + + ++ .32 .32 .32
7 K. pneumoniae OXA-48+SHV-11 + + ++ 0.5 0.75 0.25
1 E. cloacae OXA-48+TEM-1+CTX-M-15+OXA-1 + + ++ 0.5 2 0.5
2 E. cloacae OXA-48+TEM-1+CTX-M-15+OXA-1 + + ++ 1 16 1.5
1 Citrobacter koseri OXA-48 ++ + ++ 0.38 2 0.38
2 C. koseri OXA-48+TEM-1 ++ + ++ 0.75 2 0.38
1 C. freundii OXA-48+SHV-12+TEM-1 ++ + ++ 1 3 0.75
OXA-162 1 K. pneumoniae OXA-162+TEM-1+SHV-11 + + ++ 4 8 1
OXA-181 1 K. pneumoniae OXA-181+SHV-11+CTXM-15+OXA-1 + +/2 ++ 0.5 2 0.5
1 E. coli OXA-181 + + + 0.5 1.5 0.5
2 E. coli OXA-181 + +/2 +/2 0.75 2 0.5
OXA-204 1 K. pneumoniae OXA-204+CMY-4 + + ++ 0.5 2 0.5
OXA-232 1 E. coli OXA-232+CTX-M-15+OXA-1 + +/2 + .32 .32 .32
1 K. pneumoniae OXA-232 +SHV-1+TEM-1+CTX-M-15+OXA-1 + +/2 ++ 3 .32 12
OXA-244 1 E. coli OXA-244+TEM-1+CMY-2 + 2 +/2 0.5 2 0.5




K. pneumoniae SHV-11 2 2 2 0.06 0.06 0.06
acquired CPase 1 E. coli DHA-1 2 +/2 2 0.12 0.02 0.02
1 E. coli ACC-1 2 +/2 2 0.12 0.12 0.12
1 K. pneumoniae DHA-2 2 2 2 0.12 0.5 0.12
1 Proteus mirabilis ACC-1 2 +/2 2 0.25 0.12 0.12
ESBL 1 E. coli CTX-M-1 2 2 2 0.12 0.12 0.12
1 E. coli CTX-M-3 2 2 2 0.12 0.12 0.12
1 K. pneumoniae CTX-M-3 2 2 2 0.12 0.12 0.12
1 E. coli CTX-M-14 2 +/2 2 0.12 0.12 0.12
2 E. coli CTX-M-14 2 2 2 0.12 0.12 0.12
1 K. pneumoniae CTX-M-14 2 2 2 0.12 0.12 0.12
1 E. coli CTX-M-15 2 2 2 0.12 0.12 0.12
2 E. coli CTX-M-15 2 2 2 0.12 0.12 0.12









2 K. pneumoniae CTX-M-15 2 2 2 0.12 0.12 0.12
3 K. pneumoniae CTX-M-15 2 2 2 0.12 0.12 0.12
1 E. cloacae CTX-M-15 2 2 2 0.12 0.12 0.12
1 E. cloacae VEB-1 2 2 2 0.12 0.12 0.12
CPase+ impermeability 1 E. coli  Case 2 2 2 16 .32 2
1 E. cloacae  Case 2 +/2 2 0.12 1 0.12
2 E. cloacae  Case 2 2 2 0.12 1 0.12
3 E. cloacae  Case 2 2 2 0.25 4 0.25
4 E. cloacae  Case 2 +/2 2 4 1.5 0.75
5 E. cloacae  Case 2 2 2 0.19 1.5 0.12
6 E. cloacae  Case 2 2 2 0.25 1 0.12
7 E. cloacae  Case 2 2 2 0.75 2 0.12
8 E. cloacae  Case 2 2 2 0.19 1 0.12
9 E. cloacae  Case 2 +/2 2 0.25 1 0.12
10 E. cloacae  Case 2 +/2 2 0.25 1.5 0.12
11 E. cloacae  Case 2 2 2 0.38 2 0.12
12 E. cloacae  Case 2 +/2 2 0.5 1.5 0.25
13 E. cloacae  Case 2 +/2 2 1 3 0.5
14 E. cloacae  Case 2 2 2 1 2 0.5
1 Enterobacter
aerogenes
 Case 2 +/2 2 1 4 0.75
1 Morganella
morganii
 Case 2 2 2 1.5 0.02 0.12
ESBL+ impermeability 1 E. coli CTX-M-15 2 2 2 2 4 1
1 K. pneumoniae CTX-M-15+SHV-1 2 +/2 2 1 .32 4
2 K. pneumoniae CTX-M-15+TEM-1+SHV-1 2 +/2 2 1.5 .32 4
3 K. pneumoniae CTX-M-15+TEM-1+SHV-1 2 2 2 0.25 1 1
4 K. pneumoniae CTX-M-15+SHV-11 2 2 2 1.5 .32 6
5 K. pneumoniae CTX-M-15+SHV-28 - TEM-1 2 +/2 2 8 .32 4
6 K. pneumoniae TEM-1+SHV-28 2 2 2 1 4 1
7 K. pneumoniae CTX-M-15+TEM-1+SHV-11 2 2 2 3 .32 6
8 K. pneumoniae CTX-M-15+TEM-1+SHV-11 2 2 2 0.25 1 1
9 K. pneumoniae CTX-M-15+TEM-1+SHV-11 2 2 2 6 .32 .32
10 K. pneumoniae CTX-M-15+TEM-1+SHV-12 2 2 2 0.75 .32 3
11 K. pneumoniae CTX-M-15 +TEM-1+SHV-11 2 2 2 1 24 0.5
12 K. pneumoniae CTX-M-15+TEM-1+SHV-1+OXA-1 2 +/2 2 2 4 1
ESBL+CPase+ impermeability 1 E. cloacae  Case +CTX-M-15 2 2 2 1.5 6 1
2 E. cloacae  Case +CTX-M-15 2 2 2 2 8 1
3 E. cloacae  Case +CTX-M-15 2 +/2 2 3 12 2



















(95% CI 93.8%–99.3%)] determined by using a different col-
lection of strains, including Enterobacteriaceae, Pseudomonas
aeruginosa and Acinetobacter baumannii. The performance
of the Carba NP test (Table 2) was in accordance with the
performance previously described.6,11 – 13 As previously re-
ported,12,14 the Carba NP test performed better than the Rapid
CARB Screenw.
Comparison of technical features of the RAPIDECw CARBA
NP, the Rapid CARB Screenw and the Carba NP test
The technical features of the tests are summarized in Table 2. The
RAPIDECw CARBA NP requires only the material included in the kit
and a 10 mL inoculation loop. The Rapid CARB Screenw requires
additional material/equipment, as does the Carba NP test
(Table 2), and a longer time to prepare the reagents.
Although the time required for the three assays is a maximum
of 2 h, especially for detection of non-carbapenemase producers,
the detection of CPE was obtained faster with the RAPIDECw
CARBA NP and the Carba NP test compared with the Rapid CARB
Screenw. Indeed, the median time for the detection of KPC- and
MBL-producing isolates was 5 min using RAPIDECw CARBA NP
and the Carba NP test, while it was 30 min for the Rapid CARB
Screenw (Table 2). As previously reported,12 this delay to obtain
results by using the Rapid CARB Screenw is mainly due to the
time needed to dissolve the tablet containing imipenem plus
excipient (tube B) or the excipient alone (tube A) before perform-
ing the first reading at 30 min.
The performance of the RAPIDECw CARBA NP in this study
cannot be compared with any other published studies since
this study corresponds to the first evaluation of the perform-
ance of this test. The performance observed for the Rapid
CARB Screenw [sensitivity 89.5% (95% CI 81.7% –94.2%) and
specificity 70.9% (95% CI 57.9% – 81.2%)] is similar to that
previously reported by Huang et al.12 for Enterobacteriaceae
(sensitivity 87.1% and specificity 62.7%), confirming the super-
iority of the Carba NP test compared with the Rapid CARB
Screenw. In addition, as noticed by Simner et al.14 and Huang
et al.,12 the Rapid CARB Screenw was difficult to interpret com-
pared with the Carba NP test (and now the RAPIDECw CARBA
NP), mostly due to reading difficulties induced by the turbidity
of the undissolved tablet containing imipenem plus excipient
(tube B) or excipient alone (tube A) (Figure S1). Globally, the per-
formance observed for the Carba NP test [sensitivity 96.8% (95%
CI 91.1%–98.9%) and specificity 100% (95% CI 93.5%–100%)]
is in line with that reported by Yusuf et al.13 (specificity 91.1%
and specificity 100%) and Huang et al.12 (specificity 97% and sen-
sitivity 100%), and with that observed by Pasteran et al.15 for the
Blue-Carba test (specificity 97% and sensitivity 100%), a home-
made test derived from the Carba NP test.8 However, the true
performance of the Blue-Carba test as compared with the Carba
NP test shall be evaluated on an extended panel of carbapenem
producers including OXA-48-like producers.
Finally, we showed that the RAPIDECw CARBA NP is more
specific and sensitive than the Rapid CARB Screenw for detecting
any type of CPE (known and unknown carbapenemases). It is a
rapid and easy-to-handle diagnostic test for controlling the
spread of CPE by detecting any kind (known or unknown) of car-
bapenemase activity. It may find its place as a first-line screen of
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